Skip to main content
. 2019 Jun 3;14(10):949–960. doi: 10.1080/15592294.2019.1625673

Figure 2.

Figure 2.

The expression status of HOXA11-AS and HOXA11 in cisplatin (DDP)-resistant lung adenocarcinoma cell lines and tissues. Real-time PCR (a) was used to analyze the expression of HOXA11-AS and HOXA11. qMSP (b) and BSP (c) were used to evaluate their methylation statuses. HOXA11-AS expression was upregulated and HOXA11 expression was downregulated in the A549/DDP cell line, with hypermethylation of CpG 1 and CpG 2. Treatment with 5-aza-CdR (1 μM) restored HOXA11 expression and reversed the hypermethylation of the CpG islands. The HOXA11-AS and HOXA11 expression status (d) and methylation (e) were also analyzed in primary tumor cells; 20 LUAD samples were considered DDP-sensitive samples (IC50 < 5 mg/L), and 20 samples were considered DDP-resistant samples (IC50 > 10 mg/L). PMR, percentage of methylation reference.